FDA panel votes yes to recommend Pfizer vaccine
An independent advisory panel of infectious disease experts, doctors and scientists recommended Thursday that the U.S. government authorize the nation's first vaccine for people over the age of 16.
It's a major milestone in the effort to get the vaccine to hospitals and pharmacies.
After hours of drilling down into data produced from a clinical trial involving 44,000 people, the group of experts -- known as the Vaccines and Related Biological Products Advisory Committee -- voted in favor of the vaccine for people over 16 years of age.
Several members raised concerns about unknowns about the vaccine, including its potential to trigger allergic reactions and little data on how it impacts pregnant women.
Several panel members also expressed concern there wasn't enough data to support giving the vaccines to 16- and 17-year-olds.
At issue was this question: "Based on the totality of scientific evidence available, do the benefits of the Pfizer-BioNTech COVID-19 Vaccine outweigh its risks for use in individuals 16 years of age and older?"
The panel voted 17-4 that the benefits outweighed the risks. One member of the committee abstained.
The U.S. Food and Drug Administration will now take the committee's input into account in issuing an emergency use authorization.
-ABC News' Anne Flaherty